WALTHAM, Mass., May 21 /PRNewswire-FirstCall/ -- Thermo Fisher
Scientific Inc. (NYSE: TMO) and Quintiles Transnational Corp. today
announced the creation of a joint venture, called Cenduit, that provides
seamless, integrated Interactive Response Technology (IRT) services during
the clinical trial phase of drug development. IRT is a technology platform
that integrates patient interaction systems through a combination of
telephone response, Web interface and handheld electronic patient diaries.
The use of IRT is expected to grow as pharmaceutical companies look to
streamline and better control increasingly complex drug development
processes.
"Our companies have been looking for an opportunity to leverage the
particular service strengths we bring to the drug development process,"
said Marijn E. Dekkers, president and chief executive officer of Thermo
Fisher Scientific. "With Cenduit, we have combined two leaders -- the
clinical supply chain expertise of our Fisher Clinical Services business
with the clinical development expertise of Quintiles -- to offer a
scalable, seamless technology platform." The name "Cenduit" signifies the
channel through which information can move directly and freely.
Thermo Fisher contributes to the joint venture its Fisher Clinical
Services IRT operations in three locations -- Horsham, U.K.; Allentown,
Penn., USA; and Basel, Switzerland. Quintiles brings its IRT operations in
Bangalore, India, and Research Triangle Park, N.C., USA, which will also
serve as Cenduit's headquarters.
Jogin Desai, chief executive officer of Cenduit, said, "This joint
venture brings together best-in-class technology, exceptional customer
service and global clinical trial expertise to give biotechnology and
pharmaceutical companies a seamless, integrated 'one-stop' service for
support of their clinical development programs. Our efficiency and
experience in IRT services and clinical project management offers the drug
development industry a conduit to the broadest, most accurate, real-time
view of every detail in the process - and a very competitive solution."
Desai previously served as executive director of Quintiles Cardiac Safety
Services.
About Quintiles
Quintiles Transnational Corp. is powering the next generation of
healthcare by providing a broad range of professional services in drug
development, financial partnering and commercialization for the
biotechnology and healthcare industries. With 17,000 employees and offices
in more than 50 countries, it is focused on providing customer-centric
solutions that are the gold standard of the industry. For more information,
please visit the company's Web site at http://www.quintiles.com.
About Thermo Fisher Scientific
Thermo Fisher Scientific (NYSE: TMO) is the world leader in serving
science, enabling our customers to make the world healthier, cleaner and
safer. With an annual revenue rate of more than $9 billion, we employ
30,000 people and serve over 350,000 customers within pharmaceutical and
biotech companies, hospitals and clinical diagnostic labs, universities,
research institutions and government agencies, as well as environmental and
industrial process control settings. Serving customers through two premier
brands, Thermo Scientific and Fisher Scientific, we help solve analytical
challenges from routine testing to complex research and discovery. Thermo
Scientific offers customers a complete range of high-end analytical
instruments as well as laboratory equipment, software, services,
consumables and reagents to enable integrated laboratory workflow
solutions. Fisher Scientific provides a complete portfolio of laboratory
equipment, chemicals, supplies and services used in healthcare, scientific
research, safety and education. Together, we offer the most convenient
purchasing options to customers and continuously advance our technologies
to accelerate the pace of scientific discovery, enhance value for customers
and fuel growth for shareholders and employees alike. Visit
http://www.thermofisher.com.
Media Contact Information:
Lori Gorski
Phone: 781-622-1242
E-mail: lori.gorski@thermofisher.com
Website: http://www.thermofisher.com
Investor Contact Information:
Ken Apicerno
Phone: 781-622-1111
E-mail: ken.apicerno@thermofisher.com
SOURCE Thermo Fisher Scientific Inc.
 back to top
Related links:
http://www.thermofisher.com
http://www.quintiles.com
http://www.prnewswire.com/comp/877850.html /
CONTACT:
Media, Lori Gorski, +1-781-622-1242,
lori.gorski@thermofisher.com, or Investors, Ken Apicerno,
+1-781-622-1111, ken.apicerno@thermofisher.com, both of Thermo
Fisher Scientific Inc.
|
